Medical Info Login Logout

INFIAMMAZIONE DI TIPO 2
COMORBIDITÀ
INFORMAZIONI UTILI
SERVIZI PER IL MEDICO

Questo sito può utilizzare cookie di profilazione di terze parti per inviarti messaggi pubblicitari mirati e servizi in linea con le tue preferenze. Se vuoi saperne di piu` o negare il consenso a tutti o ad alcuni cookie clicca qui. Proseguendo la navigazione acconsenti all'uso dei cookie. Il consenso può essere espresso anche cliccando sul tasto OK oppure proseguendo la navigazione, anche mediante scrolling del mouse

OK

Mappa del sito

Homepage

Infiammazione di tipo 2

Comorbidità

Informazioni Utili

Servizi per il medico

Medical Info

Ricerca

Condizioni di utilizzo

Cookie Policy

Privacy Policy

Contatti

Your leaving the website

This site is intended for U.S. Healthcare Professionals only.

Do you wish to continue?

Stai abbandonando il Sito

Ti informiamo che quanto contenuto nel nuovo sito prescelto non è responsabilità di Sanofi Italia.

You are about to leave sanofi site for U.S.

Sanofi US does not review the information contained on this website and/or database for content, accuracy or completeness. Use of and access to this information is subject to the terms, limitations and conditions set by the website and/or database producer.

This site might not comply with the regulatory requirements of US

You are about to move to an Unbranded site

You are moving to an Unbranded site

Your leaving the website

This site is intended for U.S. Healthcare Professionals only.

Do you wish to continue?

Stai abbandonando il Sito

Ti informiamo che quanto contenuto nel nuovo sito prescelto non è responsabilità di Sanofi Italia.

You are about to leave sanofi site for U.S.

Sanofi US does not review the information contained on this website and/or database for content, accuracy or completeness. Use of and access to this information is subject to the terms, limitations and conditions set by the website and/or database producer.

This site might not comply with the regulatory requirements of US

You are about to move to an Unbranded site

You are moving to an Unbranded site

Mappa del sito
Condizioni di utilizzo
Cookie Policy
Privacy Policy
Bibliografia
Contatti

Sanofi S.r.l. - Direzione e Coordinamento Sanofi (Francia)
Sede legale: Viale Luigi Bodio, 37/b - 20158 Milano Cap. Soc. € 202.279.195,04 I.v.
Reg. Imprese Milano /C.F./P. IVA 00832400154 - sanofi@pec.it
©2021 Sanofi S.r.l. - Direzione e Coordinamento Sanofi (Francia)
Sito sviluppato per il territorio italiano

Email Verificata

Grazie per aver verificato il tuo indirizzo email.Una mail di conferma dei dati inseriti ti consentirà di accedere alla tua area riservata

Bibliografia

INFIAMMAZIONE DI TIPO 2

Fisiopatologia e prevalenza

Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016;15(1):35-50.
Robinson D et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161-175.
Global Initiative for Asthma. Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients. v2.0 April 2019, Pocket Guide.
Peters MC et al. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014 Feb;133(2):388-94.
Gauthier M et al. Am J Respir Crit Care Med. 2015 Sep 15;192(6):660-8.
Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet. 2015 Sep 12;386(9998):1086-96.
Fahy JV. Nat Rev Immunol. 2015 Jan;15(1):57-65.

Meccanismi molecolari

Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016;15(1):35-50.
Robinson D et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161-175.
Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet. 2015 Sep 12;386(9998):1086-96.
Junttila IS. Tuning the Cytokine Responses: An Update on interleukin (iL)-4 and iL-13 Receptor Complexes. Front Immunol. 2018 Jun 7;9:888.
Israel E & Reddel HK. Severe and Difficult-to-Treat Asthma in Adults. N Engl J Med. 2017 Sep 7;377(10):965-976.
Shinkai A et. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol. 1999 Aug 1;163(3):1602-10.
Steinke JW & Borish L. Th2 cytokines and asthma Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists Respir Res. 2001;2(2):66-70.

Marker infiammazione di tipo 2

Parulekar AD et al. Role of T2 inflammation biomarkers in severe asthma. Curr Opin Pulm Med. 2016 Jan;22(1):59-68.
Katial RK et al. Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. J Allergy Clin Immunol Pract. 2017 Mar - Apr;5(2S):S1-S14.
Prado CM et al. Nitric Oxide in Asthma Physiopathology. ISRN Allergy. 2011 Apr 19;2011:832560.
Guzik TJ et al. Nitric Oxide and Superoxide in Inflammation and Immune Regulation. J Physiol Pharmacol. 2003 Dec;54(4):469-87.
Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016;15(1):35-50.
Rosenberg HF et al. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol. 2007 Jun;119(6):1303-10.
de Vries IJ et al. Adhesion molecule expression on skin endothelia in atopic dermatitis: Effects of TNF-a and IL-4 J Allergy Clin Immunol. 1998 Sep;102(3):461-8.
Shinkai A et. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol. 1999 Aug 1;163(3):1602-10.
Global Initiative for Asthma. Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients. v2.0 April 2019, Pocket Guide.

Cascata infiammatoria

Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016;15(1):35-50.
McGregor MC et al. Role of Biologics in Asthma. Am J Respir Crit Care Med. 2019 Feb 15;199(4):433-445.

COMORBIDITÀ

Comorbidità di tipo 2

Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease Nat Rev Drug Discov 2016;15(1):35-50.
Carr S and Watson W. Eosinophilic esophagitis. Allergy Asthma Clin Immunol. 2011;7(Suppl 1):S8.

Rinosinusite cronica con poliposi nasale

Kato A. Immunopathology of chronic rhinosinusitis. Allergol Int. 2015 Apr;64(2):121-30.
Schleimer RP. Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis. Annu Rev Pathol. 2017;12:331-357.
Ceylan E et al. Nasal polyps and the severity of asthma. Respirology. 2007 Mar;12(2):272-6.
Chaaban MR et al. Epidemiology and differential diagnosis of nasal polyps. Am J Rhinol Allergy 2013;27(6):473-478.
Hulse KE et al. Pathogenesis of nasal polyposis. Clin Exp Allergy. 2015 Feb;45(2):328-46.
Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet. 2015 Sep 12;386(9998):1086-96.
Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease Nat Rev Drug Discov 2016;15(1):35-50.
Dietz de Loos DA, et al. Symptoms in chronic rhinosinusitis with and without nasal polyps. Laryngoscope. 2013 Jan;123(1):57-63.
Yamada T et al. Eotaxin-3 as a Plasma Biomarker for Mucosal Eosinophil Infiltration in Chronic Rhinosinusitis. Front Immunol. 2019 Feb 4;10:74.
Robinson D et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017 Feb;47(2):161-175.
Corren J et al. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020 Feb;8(2):516-526.
McGregor MC et al. Role of Biologics in Asthma. Am J Respir Crit Care Med. 2019 Feb 15;199(4):433-445.
Takabayashi T et al. Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression. Am J Respir Crit Care Med. 2013 Jan 1;187(1):49-57.
Stevens WW et al. Chronic rhinosinusitis with nasal polyps. J Allergy Clin lmmunol Pract 2016;4(4):565-572.
Akdis CA et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin lmmunol 2013;131(6):1479-1490.
Khan A et al. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32-42.
Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy 2016;9:45-53.
Bachert C et al. ICON: chronic rhinosinusitis. World Allergy Organ J 2014;7(1):25.
Head K et al. Short-course oral steroids alone for chronic rhinosinusitis. Cochrane Database Syst Rev 2016;4:CD011991.
Fokkens WJ et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl 2012;50(23):1-298.
Vaidyanathan S et al. Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids followed by topical steroids. Ann Intern Med 2011;154(5):293-302.
Van Zele T et al. Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy 2014;28(3):192-198.
Stevens WW et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J Allergy Clin lmmunol Pract 2017;5(4):1061-1070. 8.
De Greve G et al. Endotype‑driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017 Jul 12;7:22.
xAIFA - Farmaci biologici. Da: https://www.aifa.gov.it/farmaci-biologici [Ultimo accesso: settembre 2020].x
ISS - Farmaco chimico. Da: https://www.iss.it/farmaco-chimico. [Ultimo accesso: settembre 2020].
EMA - Medicinali biosimilari nell'UE - Guida informativa per gli operatori sanitari. Da: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_it.pdf [Ultimo accesso: settembre 2020].
Foltz IN et al. Evolution and Emergence of Therapeutic Monoclonal Antibodies. Circulation. 2013 Jun 4;127(22):2222-30.
Fokkens WJ et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464.

Dermatite atopica

Gelmetti C et al. Dermatite atopica 2016-2017. Sidemast.
Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease Nat Rev Drug Discov 2016;15(1):35-50.
Heffler E et al. The Severe Asthma Network in Italy: Findings and Perspectives. J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1462-1468.
Prescott JD et al. In Atopic Dermatitis, Looks Can Be Deceiving. Am J Manag Care 2016 (Suppl).

Message

This site is intended for use by U.S. residents only.
SAGLB.AST.18.11.1436 Date of approval: January 2019